Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by POON, R.
Right arrow Articles by VALLI, V. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by POON, R.
Right arrow Articles by VALLI, V. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 Oxford University Press

research-article

Short-Term Toxicity of Bitumen Upgrading Products in the Rat Following Repeated Dermal Exposure

R. POON*, I. CHU*,1, D. C. VILLENEUVE* and V. E. VALLI{dagger}

*Environmental Health Directorate, Health Protection Branch Ottawa, Ontario KIA 0L2, Canada {dagger}College of Veterinary Medicine, University of Illinois Urbana, Illinois 61801

Received August 4, 1993; accepted January 8, 1994

Light gas oil (B-LGO), heavy gas oil No. 1 (B-HGOI), and heavy gas oil No. 2 (B-HGOII) fractions of bitumen upgrading products (BUPs) were applied on the dorsal skin of rats at 25 mg/kg bw/day (low dose), 100 mg/kg bw/day (intermediate dose), and 400 mg/kg bw/day (high dose) for 4 weeks. Control animals received normal saline while positive controls received a medium boiling coal liquefaction product (CLP) at 100 and 400 mg/kg bw/day. Reduced food consumption and growth suppression were observed in males and females treated with B-HGOI, B-HGOII, and CLP, but only in males receiving B-LGO. Increased relative spleen, kidney, and liver weights were observed in animals treated with B-HGOI, B-HGOII, and CLP, but not in control or LGO groups. A dose-related increase in absolute and relative liver weight was most marked in animals receiving B-HGOII where a significant increase was observed starting at the low dose, followed by those receiving B-HGOI and CLP. Appearance of pale foci on the splenic capsule and increases in spleen/body weight ratio were limited to animals receiving B-HGOI and B-HGOII. Decreases in hematocrit and RBC and increase in percentage of reticulocytes were observed in animals of both sexes receiving B-HGOI and B-HGOII. Female rats appeared to be more severely affected because significant decreases in hemoglobin and RBC were observed in animals receiving the low dose of B-HGOII and the intermediate dose of B-HGO-I. Increased serum cholesterol was observed in B-HGOII-treated females at all dose levels, and in males starting at the intermediate dose. Histological changes were observed in the thymus gland, where moderate to marked cortical atrophy was noted in male and female rats receiving the high dose of B-HGOI and B-HGOII, and in the bone marrow, where the most significant abnormality was the presence of focal myelofibrosis in some male rats treated with B-HGOI and B-HGOII. Mild to moderate histological changes were found in the thyroid, liver, and spleen of rats of all treatment groups. Changes in the skin included moderate hyperkeratosis in fe males receiving high doses of B-LGO and in animals of both sexes receiving high doses of B-HGOI, and moderate to marked epidermal hyperplasia in rats receiving high doses of B-HGOI. Based on these multiple endpoints, the severity of systemic tox icity was B-HGOII > B-HGOI > CLP≥ B-LGO. The NOEL was about 25 mg/kg bw/day for B-LGO and lower than 25 mg/ kg bw/day for B-HGOI and B-HGOII.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.